Objective To construct dendritic cell(DC) vaccine expressing hepatitis C virus(HCV) multi-cytotoxic T lymphocyte(CTL) epitopes,which can stimulate T-cell response in vitro,providing certain information for immunization experiments in vivo for the next step.Methods DCs were infected with recombinant defective adenoviruses expressing two HCV CTL epitopes with tagged green fluorescent protein(GFP).The rate of infection was detected by the fluorescence microscope or flow cytometry;the expression of multiple CTL epitopes in DC was proved by RT-PCR and Western Blot.The cell surface markers of DC such as CD80,CD83,CD86 and HLA-DR were identified by flow cytometry.T cell proliferation effect promoted by DC was observed by cell counting kit-8(CCK-8).IL-12p70 in DC culture supernatant and IFN-γ in T cell supernatant were detected by Enzyme-Linked Immuno Sorbent Assay(ELISA).HCV specific CTL activity was measured by LDH release assay.Results Recombinant multi-CTL epitopes and GFP were successfully expressed in DC.Adenovirus can promote DC maturation,the percentages of CD80,CD83,CD86 and HLA-DR were(71.19±3.29)%,(81.21±5.07)%,(91.23±4.24)%,(97.95±5.31)% respectively.Infected DC promotes homologous T cell proliferation and the stimulation index was 6.806±0.247 when DC:T was 1:10.The secretion of IL-12 and IFN-γ was also increased to(193.83±6.25) pg/ml and(111.14±2.09) pg/ml respectively.The CTL stimulated by infected DC could specifically kill Huh-7.5 cells transfected with FL-J6/JFH transcripts.The cytotoxicity was 35.99% when the rate of effector to target was 100:1.Conclusion The multi-CTL epitopes recombinant adenovirus can effectively infect DC in vitro,promoting the T cell immune response,laying the foundation for developing anti-HCV DC vaccine.
[1]Stoll-Keller F,Barth H,Fafi-Kremer S,et al.Development of hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines,2009,8(3):333-345.
|
[2] 李端,薛小平,贾战生,等.中国人HCV CTL复合多表位抗原基因免疫学特性研究[J].中华肝脏病杂志,2009,17(10):786-787.
|
[3]张美先,李勤凡,李端,等.中国人丙型肝炎病毒CTL多表位肽诱发的细胞免疫应答[J].细胞与分子免疫学杂志,2010,5(26):400-402.
|
[4]马力,魏欣,张野,等.体外培养的嵌合体丙型肝炎病毒感染Huh7.5细胞的透射电镜观察[J].中华微生物学和免疫学杂志,2009,29(6):568-573.
|
[5]Steinman RM,Banchereau J.Taking dendritic cells into medicine[J].Nature,2007,449(7161):419-426.
|
[6]Lundqvist A,Noffz G,Pavlenko M,et al.Nonviral and vral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection[J].J Immunotherapy,2002,25(6):445-454.
|
[7]Diepolder HM,Gerlach JT,Zachoval R,et al.Imm-unodominant CD4+T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection[J].J Virol,1997,71(8):6011-6019.
|
[8]Wang QM,Sun SH,Hu ZL,et al.Epitope DNA vaccines against tuberculosis:spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine[J].Scand J Immunol,2004,60(3):219-225.
|
[9]Cerny A,McHutchison JG,Pasquinelli C,et al.Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif[J].J Clin Invest,1995,95(2):521-530.
|
[1] | XU Zhen, LIU ShouSheng, TAN Jie, SUN BaoKai, DU ShuiXian, XIN YongNing, XUAN ShiYing. Expression and significance of leptin and adiponectin in serum of patients with nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2478-2483. doi: 10.3969/j.issn.1001-5256.2020.11.016 |
[2] | Wang CuiHua, Yue Yan. Research progress in relationship of leptin and adiponectin with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(8): 1351-1354. doi: 10.3969/j.issn.1001-5256.2015.08.045 |
[3] | Kong Yin, Zhang LingYi. The role of leptin and adiponectin in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(4): 441-443. |
[4] | Zhao ZhengBin, Li JunFeng, Huang ShuangSheng, Zhang LiTing, Chen Hong. The advances of profibrogenic research of leptin and its signaling pathways in hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1106-1108. |
[6] | Wang ChunPing, Zhang Ming. Evaluation of leptin receptor Gln223Arg polymorphism in patients with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2008, 24(3): 194-196. |
[7] | Li Mei, Liang YingYin, Lin HongZheng, Xu Ya, Chen SongLin, Liu SiChun. Clinical analysis of 32 cases with alcoholic liver disease and alcohol with drawal syndrome[J]. Journal of Clinical Hepatology, 2007, 23(1): 38-39. |
[8] | Li YuQin, Po YunFeng, Chen ZhaoJie, Ding BaiJing, Tang TongYu, Wang Dan, Gao YanHang, Jin JingLan. Relationship between the levels of serum leptin and insulin resistance in patients with fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(5): 360-361. |
[9] | Li RuiYan, Xiong JinHu. Evaluation of the clinical value of the concentration of leptin in viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 96-97. |
[11] | Liu FengHai, Sun LinYu, Tan HaiYan, Liu XiaoLi. The clinical significance of serum leptin levels in patients with nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2006, 22(1): 41-42. |
[12] | Zheng JiMin, Jiang HuiQing, Lu: XiaoPing, Zhang XiangMei. Measurement of ghrelin leptin levels in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2006, 22(3): 195-196. |
[13] | Lu ZhenYa, Wang QunYan, Rao WeiQiang, Cai WeiMin. Relationship between leptin resistance and nonalcoholic fatty liver in male patients.[J]. Journal of Clinical Hepatology, 2006, 22(1): 39-41. |
[14] | Wang RuiKe, Liu XiuZhen, Zhang GuYun, Li Hong, Sun ZhaoCui, Zhang JinAn. Monitoring the change of interleukin-6 in the alcoholic liver disease and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(2): 100-101. |
[15] | Wang HaiQin, Li JuanJuan. Therapeutic effect of GSH on the treatment of alcoholic liver diseases.[J]. Journal of Clinical Hepatology, 2004, 20(6): 355-356. |
[16] | Li ChuanFeng, Huang YongCan, Qiu Xiang, Po YunFeng. Clinical analysis of 146 cases of alcoholic liver diseases.[J]. Journal of Clinical Hepatology, 2004, 20(3): 157-158. |
[17] | Lu ZhenYa, Wang QunYan, Rao WeiQiang, Cai WeiMin, Liu RongHua. The relationship between serum leptin levels and the levels of fibrosis marks in patients with hepatitis B.[J]. Journal of Clinical Hepatology, 2004, 20(2): 85-86. |